April 19, 2024
2 min read
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic.
Subcutaneous Entyvio (vedolizumab, Takeda Pharmaceuticals) was previously approved in 2023 for moderate-to-severe ulcerative colitis. The company noted that the drug is also currently available in the United States as the single-dose pre-filled Entyvio Pen.
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic.
The FDA based its decision on results from VISIBLE 2, a phase 3, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of subcutaneous (SC) vedolizumab as maintenance therapy in adults with moderate-to-severe CD. Of the patients that achieved clinical response at week 6 after two doses of open-label IV vedolizumab at weeks 0 and 2, researchers randomly assigned 409 patients 2:1 at week 6 to receive either SC vedolizumab 108 mg or placebo by SC injection every 2 weeks.
According to study results, at week 52, a statistically significantly proportion of patients who received SC vedolizumab maintenance therapy achieved clinical remission —defined as total CDAI score of 150 — compared with those who received placebo (48% vs. 34%; P <0.01).
“Crohn’s disease is a complex and usually progressive disease for which an appropriate management plan is critical; my primary goal as a clinician is always to get patients to achieve remission,” Timothy Ritter, MD, senior medical director at GI Alliance Research and assistant professor of medicine at TCU School of Medicine in Fort Worth, Texas, said in a press release. “In VISIBLE 2, about half of patients treated with Entyvio SC achieved long-term clinical remission. The data from VISIBLE 2 reaffirm the well-established efficacy profile of Entyvio, regardless of route of administration.”
The safety profile of SC vedolizumab was consistent with the previously established safety profile, other than injection site reactions such as injection site erythema, rash, swelling, bruising and hematoma with SC administration, the company reported. The most common adverse events reported were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain and pain in extremities.
“The approval of subcutaneous Entyvio in Crohn’s disease delivers on our goal of providing treatment options that can help patients achieve remission of their ulcerative colitis or Crohn’s disease, while also providing them flexibility and choice of route of administration,” Brandon Monk, senior vice president and head of the U.S. Gastroenterology Business Unit at Takeda, said in the release. “With Entyvio Pen, patients have the option of administering their maintenance treatment at home or on-the-go. Our development of a subcutaneous option demonstrates Takeda’s commitment to meeting the very real needs of those living with gastrointestinal diseases.”
Published by:
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
